In the interest of time can we just take one question per participant I can see a long queue here.
Shyam, the footnote that you are mentioning relates to divestment of an Organon product which they have already done.
Questions across 10 calls
Abhishek Sharma
Firm not listed in source transcripts
Sun Pharmaceutical Industries Limited
Sorry, which product?
Yes, that's right.
That we don't disclose, Damayanti.
Yes. So Damayanti, Q1 lenalidomide sales were moderately higher versus Q4. Moderately.
So Kunal, Leqselvi moved from intangibles under development into intangibles.
No, then the rest are several small items. It's largely Checkpoint and Leqselvi.
Thank you. Everyone, for joining us at this late hour. If any of your questions remain unanswered, you can get back to the Investor Relations team or to me, and we'll be happy to take those separately. Thank you.
Saion, for this quarter the contribution from Lenalidomide was not large.
Nimish is still pretty much top of mind, Abhishek here. Thanks everyone for joining the call at this late hour. For any questions that still remain unanswered, you can reach out to the Investor Relations team, and we will be happy to take your questions. Thank you.
Thank you everyone for joining us at this late hour. If any of your questions have remained unanswered, you can reach out to me or Investor Relations team. Thank you and good evening. Thank you.
While Abhay will answer this question, we don't talk about Taro separately, Shashank.
Yes, sure. Let Abhay answer the question.
Aman, you can connect with me offline on these questions.
Thank you, Reo. Thanks, everyone, for dialing in. If you have any unanswered questions, you can reach out to the Investor Relations team. We'll be happy to take your questions offline. Thank you and have a good evening.
Thanks, everyone, for joining us at this late hour. If you have any unanswered questions, please do feel free to contact me, get in touch with us. We'll be happy to address all your questions. Thank you.